CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

NCT03636269 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

473

Enrollment

INDUSTRY

Sponsor class

Conditions

Uremic Pruritus

Interventions

DRUG: CR845 0.5 mcg/kg
DRUG: Placebo

Sponsor

Cara Therapeutics, Inc.